Eichhorst, B, Niemann, C, Kater, AP, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, PB, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, CB, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, MBL, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, HR, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, MHJ, Geisler, CH, Stilgenbauer, S & Hallek, M 2021, '
A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial',
Blood, bind 138, nr. Suppl. 1, 71.
https://doi.org/10.1182/blood-2021-146161